ONCT Oncternal Therapeutics
- 1.3500
- -0.0800-5.59%
- 1.4200
- +0.0700+5.19%
Oncternal Therapeutics News
Oncternal Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Oncternal Therapeutics | 8-K: Current report
Oncternal Therapeutics | 10-Q: Q2 2024 Earnings Report
Oncternal Therapeutics | 8-K: Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director KISNER DANIEL L
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director CARTER MICHAEL G
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director DeSimone Jill
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director THEUER CHARLES
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HALE DAVID F
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director LARUE WILLIAM R
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 8-K: Current report
Oncternal Therapeutics | 10-Q: Q1 2024 Earnings Report
Oncternal Therapeutics | 8-K: Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Oncternal Therapeutics | EFFECT: Others
Oncternal Therapeutics | CORRESP: CORRESP
Oncternal Therapeutics | ARS: Annual Report to Security Holders
Oncternal Therapeutics | DEFA14A: Others
Oncternal Therapeutics | DEF 14A: Definitive information statements
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Analysis
Price Target
No Data
No Data
